MCID: TNG009
MIFTS: 59

Tongue Squamous Cell Carcinoma malady

Categories: Cancer diseases, Oral diseases, Gastrointestinal diseases

Aliases & Classifications for Tongue Squamous Cell Carcinoma

About this section

Aliases & Descriptions for Tongue Squamous Cell Carcinoma:

Name: Tongue Squamous Cell Carcinoma 35 11 13
Squamous Cell Carcinoma of Tongue 68
 
Carcinoma, Squamous Cell 39

Classifications:



External Ids:

Disease Ontology11 DOID:0050865
MeSH39 D002294
NCIt45 C2929

Summaries for Tongue Squamous Cell Carcinoma

About this section
Disease Ontology:11 A head and neck squamous cell carcinoma that is located in the tongue.

MalaCards based summary: Tongue Squamous Cell Carcinoma, also known as squamous cell carcinoma of tongue, is related to squamous cell carcinoma of the oral tongue and squamous cell carcinoma. An important gene associated with Tongue Squamous Cell Carcinoma is DND1 (DND MicroRNA-Mediated Repression Inhibitor 1), and among its related pathways are RHO GTPases activate IQGAPs and Platinum drug resistance. Affiliated tissues include the tongue, tongue and lymph node, and related mouse phenotypes are pigmentation and renal/urinary system.

Related Diseases for Tongue Squamous Cell Carcinoma

About this section

Diseases related to Tongue Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 112)
idRelated DiseaseScoreTop Affiliating Genes
1squamous cell carcinoma of the oral tongue11.1
2squamous cell carcinoma11.0
3clear cell adenofibroma10.3CDKN2A, TP53
4lacrimal gland adenoid cystic carcinoma10.3CDKN2A, TP53
5chondrodysplasia punctata, rhizomelic, type 310.3CASP3, TP53
6congenital sucrase-isomaltase deficiency without sucrose intolerance10.3NOTCH1, TP53
7facio skeletal genital syndrome rippberger type10.3MMP2, MMP9
8pericardium leiomyoma10.3CDKN2A, TP53
9linitis plastica10.3CDH1, TP53
10brain stem medulloblastoma10.2CDKN2A, NOTCH1, TP53
11fallopian tube adenocarcinoma10.2CASP3, CDKN2A, TP53
12cutaneous adenocystic carcinoma10.2BSG, NOTCH1, TP53
13acute tricyclic antidepressant poisoning10.2MMP2, MMP9
14neuropathy, hereditary sensory, type id10.2MMP14, MMP2
15striated muscle rhabdoid tumor10.2CDKN2A, MMP2, MMP9
16diffuse large b-cell lymphoma10.2HIF1A, MMP1, MMP9
17adenoid squamous cell carcinoma10.2CDKN2A, MMP2, MMP9
18anisomastia10.2MMP14, MMP2
19breast leiomyoma10.2CDKN2A, MMP2, TP53
20spastic hemiplegia10.2HIF1A, MMP1, MMP9
21kleptomania10.2MMP1, MMP2, MMP9
22estrogen-receptor positive breast cancer10.2CDH1, CDKN2A, TP53
23fallopian tube leiomyosarcoma10.2CDH1, CDKN2A, TP53
24pyomyositis10.1CDH1, CDKN2A, TP53
25retinal drusen10.1MMP2, MMP9, NOTCH1
26papillary transitional carcinoma10.1CASP3, CDH1, TP53
27onychocytic matricoma10.1MMP1, MMP2, MMP9
28lower lip cancer10.1CASP3, MMP2, MMP9
29melanoma metastasis10.1BMI1, CASP3, CDKN2A, TP53
30laryngostenosis10.1MMP1, MMP2, MMP9
31adenocarcinoma in situ10.1MMP14, MMP2, MMP9
32breast abscess10.1MMP1, MMP2, MMP9
33dental caries10.1CDH1, MMP2, TP53
34chronic polyneuropathy10.1MMP2, MMP9, NOTCH1
35nasal cavity disease10.1CDH1, MMP2, TP53
36progesterone-receptor positive breast cancer10.1CDH1, CDKN2A, TP53
37metagonimiasis10.1MMP2, TP53, VEGFC
38marginal zone b-cell lymphoma10.1CDKN2A, MMP2, MMP9, TP53
39maxillary neoplasm10.1CDH1, MMP2, MMP9
40breast papillary carcinoma10.1CDH1, MMP2, MMP9
41progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 310.1CDKN2A, MMP2, MMP9, TP53
42mitochondrial encephalomyopathy10.1CDKN2A, MMP14, MMP2, TP53
43sternum lymphoma10.1CDH2, CDKN2A, TP53
44connective tissue benign neoplasm10.1CASP3, CDH1, CDKN2A, TP53
45hypoxia10.1
46glucosephosphate isomerase deficiency10.1CDKN2A, MMP2, MMP9, TP53
47senile atrophy of choroid10.1CASP3, MMP1, MMP2, MMP9
48adrenal cortical carcinoma10.1CASP3, CDH1, CDKN2A, TP53
49subglottis neoplasm10.1CDKN2A, MMP1, MMP14, MMP2
50endotheliitis10.0

Graphical network of the top 20 diseases related to Tongue Squamous Cell Carcinoma:



Diseases related to tongue squamous cell carcinoma

Symptoms & Phenotypes for Tongue Squamous Cell Carcinoma

About this section

MGI Mouse Phenotypes related to Tongue Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

41 (show all 21)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011868.7CASP3, CDKN2A, CTNNB1, NOTCH1, SNAI2, TP53
2MP:00053677.9CASP3, CTNNB1, HIF1A, MMP14, MMP9, NOTCH1
3MP:00053827.6CASP3, CTNNB1, HIF1A, MMP14, MMP2, NOTCH1
4MP:00020067.4CDH1, CDKN2A, CTNNB1, DND1, HIF1A, MMP1
5MP:00053807.2CDH1, CDH2, CDKN2A, CTNNB1, HIF1A, MMP14
6MP:00053897.1BSG, CASP3, CDH1, CDKN2A, CTNNB1, DND1
7MP:00053847.1CASP3, CDH1, CDH2, CDKN2A, CTNNB1, HIF1A
8MP:00053697.0CASP3, CDH2, CDKN2A, CTNNB1, HIF1A, MMP14
9MP:00053886.8BSG, CASP3, CDKN2A, CTNNB1, HIF1A, MMP14
10MP:00053916.6CASP3, CDKN2A, CTNNB1, HIF1A, MMP14, MMP2
11MP:00053906.5CASP3, CDKN2A, CTNNB1, HIF1A, MMP14, MMP2
12MP:00053816.4CASP3, CDH1, CDKN2A, CTNNB1, HIF1A, MMP14
13MP:00053796.2BSG, CASP3, CDH1, CDKN2A, CTNNB1, DND1
14MP:00107716.2CASP3, CDH1, CDKN2A, CTNNB1, HIF1A, MMP14
15MP:00036316.0CASP3, CDH2, CDKN2A, CTNNB1, HIF1A, MMP14
16MP:00053855.6CASP3, CDH1, CDH2, CDKN2A, CTNNB1, HIF1A
17MP:00053975.6BSG, CASP3, CDKN2A, CTNNB1, HIF1A, MMP14
18MP:00053785.5BSG, CASP3, CDH1, CDH2, CDKN2A, CTNNB1
19MP:00053765.3CASP3, CDH1, CDH2, CDKN2A, CTNNB1, HIF1A
20MP:00107685.1BSG, CASP3, CDH1, CDH2, CDKN2A, CTNNB1
21MP:00053875.1BSG, CASP3, CDH1, CDKN2A, CTNNB1, HIF1A

Drugs & Therapeutics for Tongue Squamous Cell Carcinoma

About this section

Drugs for Tongue Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 171)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
CetuximabapprovedPhase 3, Phase 2, Phase 1752205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
 
Cetuximabum
Cétuximab
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
cetuximab
2
CisplatinapprovedPhase 3, Phase 2, Phase 1277015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
3
AldesleukinapprovedPhase 340585898-30-2, 110942-02-4
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
 
Interleukin-2 aldesleukin
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
4
Fentanylapproved, illicit, investigational, vet_approvedPhase 3821437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
5
CarboplatinapprovedPhase 3, Phase 1, Phase 2205041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
6
PilocarpineapprovedPhase 32754-71-7, 92-13-75910
Synonyms:
(+)-Pilocarpine
(3S,4R)-3-Ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone
(3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one
(3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
(3S,4R)-3-ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone
(3S-cis)-3-Ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone
(3S-cis)-3-Ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone
(3S-cis)-3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone
3-Ethyl-4-(3-methyl-3H-imidazol-4-ylmethyl)dihydrofuran-2-one
3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydro-2(3H)-furanone
3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one
3-ethyl-4-((1-methyl-1H-imidazol-5-yl)methyl)dihydro-2(3H)-furanone
3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
54-71-7
91484-73-0
92-13-7
AC1L1J0W
AC1L1LEF
AC1Q6MOP
AI3-50523
AR-1F3128
Adsorbocarpine
Almocarpine
Amistura P
BIDD:GT0217
BPBio1_000548
BRD-K85090592-008-05-2
BSPBio_000498
BSPBio_002191
C07474
CHEBI:39460
CHEBI:8207
CHEMBL550
CID4819
CID5910
D00525
DB01085
DivK1c_000358
EINECS 202-128-4
Epicar
HMS2089K17
HSDB 3163
IDI1_000358
Imidazole-5-butyric acid, alpha-ethyl-beta-(hydroxymethyl)-1-methyl-, gamma-lactone
Isopto carpine
Isoptocarpine
KBio1_000358
KBio2_001587
KBio2_004155
KBio2_006723
KBio3_001691
KBioGR_000956
KBioSS_001587
L001181
LS-187208
LS-7661
Lopac0_000950
Lopac0_000960
Mi-Pilo
Minims Pilocarpine
Miocarpine
MolPort-002-512-506
NCGC00023339-03
 
NCGC00023339-06
NCGC00023339-07
NCGC00023339-08
NCGC00023339-09
NCGC00023339-12
NCGC00023339-13
NCI60_004403
NINDS_000358
NSC5746
Ocu-Carpine
Ocusert
Ocusert P 20
Ocusert Pilo-40
Ocusert pilo
Ocusert pilo-20
Ocusert pilo-20 (TN)
P.V. Carpine Liquifilm
Pilagan
Pilocarpin
Pilocarpine
Pilocarpine (JAN/USP)
Pilocarpine HCl
Pilocarpine Mononitrate, (3S-cis)-Isomer
Pilocarpine [USAN:BAN:JAN]
Pilocarpine chloride
Pilocarpine hydrochloride
Pilocarpine monohydrochloride
Pilocarpine muriate
Pilocarpine nitrate
Pilocarpine, Monohydrochloride, (3S-cis)-Isomer
Pilocarpol
Pilokarpin
Pilokarpin monohydrochloride
Pilokarpol
Piloptic-1
Piloptic-1/2
Piloptic-2
Piloptic-3
Piloptic-4
Piloptic-6
Pilostat
Prestwick0_000449
Prestwick1_000449
Prestwick2_000449
Prestwick3_000449
SDCCGMLS-0003164.P005
SPBio_001287
SPBio_002437
STOCK1N-18408
Salagen
Spectrum2_001284
Spectrum3_000546
Spectrum4_000478
Spectrum5_001379
Spectrum_001107
Spersacarpine
Spersacarpine hydrochloride
Syncarpine
Tocris-0694
UNII-01MI4Q9DI3
ZINC00075008
beta-Pilocarpine hydrochloride
isopilocarpine
nchembio.78-comp9
pilocarpine
7
FluorouracilapprovedPhase 3, Phase 2, Phase 1185651-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
8
Bevacizumabapproved, investigationalPhase 3, Phase 22020216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
9
DoxepinapprovedPhase 3131668-19-5667477, 667468
Synonyms:
(3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
(3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
(3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine
(3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
(3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
(Z)-Doxepin
11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine
11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin
11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin
1668-19-5
3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine
3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
3607-18-9
AC1L1FAW
AC1LDI5F
AC1LDI63
AC1NUW4A
AKOS001582771
Adapin
Aponal
BPBio1_000118
BRD-K36616567-003-01-5
BRD-K37694030-003-02-8
BRD-K54462405-003-03-3
BSPBio_000106
BSPBio_001934
C06971
C19H21NO
CAS-1229-29-4
CCRIS 9176
CHEBI:36691
CHEBI:36692
CHEBI:4710
CHEMBL101740
CID10039438
CID3158
CID5462131
CID667468
CID667477
Cidoxepin
Cidoxepin [INN]
Cidoxepina
Cidoxepinum
Curatin
D07875
DB01142
DivK1c_000431
Doxepin
Doxepin (INN)
Doxepin (Z)-isomer
Doxepin Hcl
Doxepin Hydrochloride,
Doxepin [USAN]
 
Doxepin, Hydrochloride
Doxepina
Doxepina [INN-Spanish]
Doxepine
Doxepinum
Doxepinum [INN-Latin]
HSDB 3069
IDI1_000431
KBio1_000431
KBio2_001285
KBio2_003853
KBio2_006421
KBio3_001154
KBioGR_001131
KBioSS_001285
L000699
LS-174582
LS-61638
Lopac-D-4526
Lopac0_000339
MF 10
MOLI001594
MolPort-003-847-024
MolPort-005-933-834
N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine
NCGC00015344-01
NCGC00015344-02
NCGC00015344-04
NCGC00024623-01
NCGC00024623-02
NCGC00162127-01
NINDS_000431
Oprea1_473232
Prestwick0_000263
Prestwick1_000263
Prestwick2_000263
Prestwick3_000263
Quitaxon
SPBio_000206
SPBio_002325
Sinequan
Sinequan (TN)
Spectrum2_000133
Spectrum3_000407
Spectrum4_000526
Spectrum5_001051
Spectrum_000805
Tocris-0508
Triadapin
UNII-5ASJ6HUZ7D
UNII-F96TTB8728
Zonalon
cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin
cis-doxepin
doxepin
10
SuccinylcholineapprovedPhase 3, Phase 2169306-40-15314
Synonyms:
2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
2ha2
2ha6
306-40-1
4-04-00-01451 (Beilstein Handbook Reference)
541-19-5 (diiodide)
55-94-7 (dibromide)
71-27-2 (dichloride)
AC1L1K2T
Anectine
BRN 1805311
C07546
C14H30N2O4
CHEBI:45652
CHEMBL703
CID5314
Choline, succinate (2:1) (ester)
Choline, succinate (ester)
DB00202
Diacetylcholine
Dicholine succinate
Ditilin
Ditiline
HMS2090P14
HSDB 3254
InChI=1/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
L000926
LS-53328
Listenon
 
Lopac-S-8251
Lopac0_001080
Lysthenon
MolPort-002-964-486
NCGC00015971-01
NCGC00015971-03
NCGC00162336-01
Quelicin
Quelicin Preservative Free
SCK
ST50437287
STK177290
Scoline
Succicuran
Succinic acid, diester with choline
Succinic acid, diester with choline chloride
Succinocholine
Succinoylcholine
Succinyl choline
Succinylbischoline
Succinylcholine
Succinylcholine Chloride
Succinyldicholine
Sucostrin
Suxamethonium
Suxamethonium chloride
UNII-J2R869A8YF
ZINC01530820
succinylcholine
succinyldicholine
trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio
trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
11
Histamineapproved, investigationalPhase 3, Phase 2105075614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-(4-imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
4-imidazoleethylamine
5-Imidazoleethylamine
5-imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminoethylglyoxaline
beta-aminoethylimidazole
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
12
BleomycinapprovedPhase 315911056-06-75360373
Synonyms:
(betaR)-N(alpha)-{[6-amino-2-((1S)-3-amino-1-{[(2S)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl)-5-methylpyrimidin-4-yl]carbonyl}-beta-{2-O-[3-O-(aminocarbonyl)-alpha-D-mannopyranosyl]-alpha-L-gulopyranosyloxy}-N-[(1R,2S,3S)-5-({(1S,2R)-1-[({2-[4-({[3-(dimethylsulfonio)propyl]amino}carbonyl)-2,4'-bi-1,3-thiazol-2'-yl]ethyl}amino)carbonyl]-2-hydroxypropyl}amino)-3-hydroxy-4-methyl-5-oxopentan-2-yl]-L-histidinamide
11056-06-7
11116-31-7
1400-95-9
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
37208-04-1
37293-16-6
37353-43-8
9041-93-4
9041-93-4 (sulfate (salt))
AC1L9UFF
AC1NSEJD
AC1NUTOQ
BLM
Blenoxane
Bleo
Bleocin
Bleogin
Bleomicin
Bleomicina
Bleomicina [INN-Spanish]
Bleomycin A(2)
Bleomycin A2
Bleomycin A2 & Bleomycin B2.
Bleomycin B(2)
Bleomycin B2
Bleomycin sulfate
Bleomycin sulphate
 
Bleomycine
Bleomycine [INN-French]
Bleomycins
Bleomycinum
Bleomycinum [INN-Latin]
C06854
C55H85N17O21S3
C55H86N17O21S3
CCRIS 2754
CHEBI:3139
CHEMBL403664
CID456190
CID5360373
CID5460769
DB00290
EINECS 234-356-5
HSDB 3208
LMPK14000006
LS-44860
LS-524
N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide
N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
NDC 0015-3010
NSC 125066
Pingyangmyvin A2
STOCK1N-74760
UNII-13M89UEA7W
UNII-40S1VHN69B
Zhengguangmycin A2
Zhengguangmycin A2 [Chinese]
bleomycin
bleomycin a2
13
Docetaxelapproved, investigational, Approved May 1996Phase 3, Phase 2, Phase 11967114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
14Interleukin-2Phase 3571
15Antiviral AgentsPhase 3, Phase 29967
16Angiogenesis InhibitorsPhase 3, Phase 2, Phase 14257
17Angiogenesis Modulating AgentsPhase 3, Phase 2, Phase 14185
18AntimetabolitesPhase 3, Phase 2, Phase 112054
19Antimitotic AgentsPhase 3, Phase 2, Phase 15657
20Immunosuppressive AgentsPhase 3, Phase 1, Phase 213086
21Liver ExtractsPhase 3, Phase 2, Phase 14067
22Antimetabolites, AntineoplasticPhase 3, Phase 2, Phase 17361
23Anti-Infective AgentsPhase 3, Phase 2, Phase 122062
24Anti-HIV AgentsPhase 3, Phase 23162
25Anti-Retroviral AgentsPhase 3, Phase 23296
26ImmunoglobulinsPhase 3, Phase 2, Phase 16394
27Antibiotics, AntitubercularPhase 3, Phase 1, Phase 27180
28Cholinergic AgentsPhase 33992
29MitogensPhase 3, Phase 2, Phase 11617
30Anti-Bacterial AgentsPhase 3, Phase 1, Phase 211226
31AntibodiesPhase 3, Phase 2, Phase 16394
32AnalgesicsPhase 3, Phase 211733
33Antibodies, MonoclonalPhase 3, Phase 2, Phase 14039
34Adjuvants, AnesthesiaPhase 31674
35Autonomic AgentsPhase 3, Phase 210150
36Neurotransmitter AgentsPhase 3, Phase 218340
37Peripheral Nervous System AgentsPhase 3, Phase 223689
38AnestheticsPhase 3, Phase 29596
39Analgesics, OpioidPhase 33238
40pancreatic polypeptidePhase 320
41NarcoticsPhase 33646
42Anesthetics, GeneralPhase 32934
43VaccinesPhase 3, Phase 16611
44Anesthetics, IntravenousPhase 32538
45Central Nervous System DepressantsPhase 3, Phase 213403
46Histamine AntagonistsPhase 3, Phase 2961
47Psychotropic DrugsPhase 36430
48
Histamine PhosphatePhase 3, Phase 2104951-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
 
EINECS 200-118-4
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
LS-78569
UNII-QWB37T4WZZ
49Endothelial Growth FactorsPhase 3382
50Neuromuscular AgentsPhase 3, Phase 21180

Interventional clinical trials:

(show top 50)    (show all 102)
idNameStatusNCT IDPhase
1Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or OropharynxUnknown statusNCT00002702Phase 3
2PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck CancerUnknown statusNCT00720070Phase 3
3Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck PatientsCompletedNCT01439724Phase 3
4Phase II Trial of Allovectin-7® for Head and Neck CancerCompletedNCT00050388Phase 3
5Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck CancerCompletedNCT00003139Phase 3
6Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
7Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive TractCompletedNCT00765440Phase 3
8Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck CancerRecruitingNCT00956007Phase 3
9Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT00588770Phase 3
10Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck CancerActive, not recruitingNCT01810913Phase 2, Phase 3
11Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without ChemotherapyActive, not recruitingNCT01156142Phase 3
12Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal CarcinomaNot yet recruitingNCT02984410Phase 3
13Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell CarcinomaSuspendedNCT00198328Phase 3
14Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of RecurrenceWithdrawnNCT01142414Phase 3
15Trial of E10A in Head and Neck CancerUnknown statusNCT00634595Phase 2
16Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Cisplatin, and Cetuximab Given Together With Radiation Therapy in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck CancerUnknown statusNCT00851877Phase 1, Phase 2
17Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck CancerUnknown statusNCT00833261Phase 2
18Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck CancerUnknown statusNCT00625937Phase 2
19External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain MetastasesUnknown statusNCT00637637Phase 2
20Rapamycin Therapy in Head and Neck Squamous Cell CarcinomaCompletedNCT01195922Phase 1, Phase 2
21Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT00103259Phase 2
22Cetuximab and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Oropharynx Cancer That Can Be Removed by SurgeryCompletedNCT00665392Phase 2
23Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx CancerCompletedNCT01084083Phase 2
24Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and NeckCompletedNCT00033618Phase 2
25Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00507767Phase 2
26Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck CancerCompletedNCT00114283Phase 2
27Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00513435Phase 2
28Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent CetuximabCompletedNCT00939627Phase 2
29Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck CancerCompletedNCT00458978Phase 2
30Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing SurgeryCompletedNCT02007200Phase 2
31Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by SurgeryCompletedNCT01333085Phase 1, Phase 2
32Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck CancerCompletedNCT00875849Phase 2
33S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00096512Phase 2
34Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous TherapyCompletedNCT01256385Phase 2
35Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck CancerCompletedNCT00423930Phase 2
36Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or PharynxCompletedNCT00064103Phase 1, Phase 2
37Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral TongueRecruitingNCT02985255Phase 2
38A Dye for the Detection of Cancer of the Tongue and MouthRecruitingNCT03085147Phase 1, Phase 2
39Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized StudyRecruitingNCT02748707Phase 2
40Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral CavityRecruitingNCT02295540Phase 1, Phase 2
41Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction DesignRecruitingNCT02128906Phase 2
4218F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyRecruitingNCT01806675Phase 1, Phase 2
43Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)Active, not recruitingNCT01312350Phase 2
44Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckActive, not recruitingNCT02035527Phase 1, Phase 2
45Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell CancerActive, not recruitingNCT01316757Phase 2
46Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal CancerActive, not recruitingNCT02254278Phase 2
47Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.Active, not recruitingNCT01469429Phase 1, Phase 2
48PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck CancerActive, not recruitingNCT01816984Phase 1, Phase 2
49CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENTNot yet recruitingNCT01760811Phase 1, Phase 2
50Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse EventsNot yet recruitingNCT03107182Phase 2

Search NIH Clinical Center for Tongue Squamous Cell Carcinoma


Cochrane evidence based reviews: carcinoma, squamous cell

Genetic Tests for Tongue Squamous Cell Carcinoma

About this section

Anatomical Context for Tongue Squamous Cell Carcinoma

About this section

MalaCards organs/tissues related to Tongue Squamous Cell Carcinoma:

36
Tongue, Lymph node, T cells, Skeletal muscle, Endothelial, Neutrophil, Smooth muscle

FMA organs/tissues related to Tongue Squamous Cell Carcinoma:

17
The tongue

Publications for Tongue Squamous Cell Carcinoma

About this section

Articles related to Tongue Squamous Cell Carcinoma:

(show top 50)    (show all 258)
idTitleAuthorsYear
1
Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma. (27932243)
2017
2
miR-373-3p Targets DKK1 to Promote EMT-Induced Metastasis via the Wnt/I^-Catenin Pathway in Tongue Squamous Cell Carcinoma. (28337453)
2017
3
Upregulated long non-coding RNA LINC00152 expression is associated with progression and poor prognosis of tongue squamous cell carcinoma. (28367232)
2017
4
Radiosensitization of oral tongue squamous cell carcinoma by nanosecond pulsed electric fields (nsPEFs). (27676191)
2017
5
Circadian Clock Gene Bmal1 Inhibits Tumorigenesis and Increases Paclitaxel Sensitivity in Tongue Squamous Cell Carcinoma. (27821487)
2017
6
hsa-miR-485-5p reverses epithelial to mesenchymal transition and promotes cisplatin-induced cell death by targeting PAK1 in oral tongue squamous cell carcinoma. (28535002)
2017
7
Expression and Clinical Significance of Concomitant FAK/SRC and p-Paxillin in Mobile Tongue Squamous Cell Carcinoma. (28314297)
2017
8
Receptor for advanced glycation end product blockade enhances the chemotherapeutic effect of cisplatin in tongue squamous cell carcinoma by reducing autophagy and modulating the Wnt pathway. (27831944)
2017
9
Nomograms to estimate long-term overall survival and tongue cancer-specific survival of patients with tongue squamous cell carcinoma. (28411370)
2017
10
MicroRNA and protein profiles in invasive versus non-invasive oral tongue squamous cell carcinoma cells in vitro. (27773646)
2017
11
Trichostatin A increases radiosensitization of tongue squamous cell carcinoma via miRa89375. (27878285)
2017
12
Occult level IV metastases in clinically node-negative patients with oral tongue squamous cell carcinoma. (27095552)
2016
13
BCL-2 inhibition impairs mitochondrial function and targets oral tongue squamous cell carcinoma. (27722045)
2016
14
A Minimal DNA Methylation Signature in Oral Tongue Squamous Cell Carcinoma Links Altered Methylation with Tumor Attributes. (27288358)
2016
15
HMGA2 is associated with the aggressiveness of tongue squamous cell carcinoma. (27809392)
2016
16
The downregulation of ANGPTL4 inhibits the migration and proliferation of tongue squamous cell carcinoma. (27505034)
2016
17
Regulatory T cells function at the early stage of tumor progression in a mouse model of tongue squamous cell carcinoma. (27614428)
2016
18
The anterolateral thigh flap for soft tissue reconstruction in patients with tongue squamous cell carcinoma. (27514796)
2016
19
miRNA-335 and miRNA-182 affect the occurrence of tongue squamous cell carcinoma by targeting survivin. (27698823)
2016
20
MicroRNA-21 regulates prostaglandin E2 signaling pathway by targeting 15-hydroxyprostaglandin dehydrogenase in tongue squamous cell carcinoma. (27561985)
2016
21
High relative density of lymphatic vessels predicts poor survival in tongue squamous cell carcinoma. (27328960)
2016
22
Toll-like receptors 2, 4, and 9 in primary, metastasized, and recurrent oral tongue squamous cell carcinomas. (26426362)
2016
23
Proapoptotic Activity of Propolis and Their Components on Human Tongue Squamous Cell Carcinoma Cell Line (CAL-27). (27281369)
2016
24
Efficacy of Elective Neck Dissection in T1/T2N0M0 Oral Tongue Squamous Cell Carcinoma: A Population-Based Analysis. (27165672)
2016
25
Decreased miR-320a promotes invasion and metastasis of tumor budding cells in tongue squamous cell carcinoma. (27582550)
2016
26
Long non-coding RNA NKILA inhibits migration and invasion of tongue squamous cell carcinoma cells via suppressing epithelial-mesenchymal transition. (27613832)
2016
27
Cancer stem cells in moderately differentiated oral tongue squamous cell carcinoma express components of the renin-angiotensin system. (27371611)
2016
28
miR-183 Modulates Cell Apoptosis and Proliferation in Tongue Squamous Cell Carcinoma SCC25 Cell Line. (28281960)
2016
29
HPV Infection and Prognostic Factors of Tongue Squamous Cell Carcinoma in Different Ethnic Groups from Geographically Closed Cohort in Xinjiang, China. (27034835)
2016
30
Correlation between clinical and MRI assessment of depth of invasion in oral tongue squamous cell carcinoma. (27876067)
2016
31
Reduced serum levels of syndecan-1 in patients with tongue squamous cell carcinoma. (26667395)
2016
32
A monomer purified from Paris polyphylla (PP-22) triggers S and G2/M phase arrest and apoptosis in human tongue squamous cell carcinoma SCC-15 by activating the p38/cdc25/cdc2 and caspase 8/caspase 3 pathways. (27644244)
2016
33
Interleukin-17A promotes tongue squamous cell carcinoma metastasis through activating miR-23b/versican pathway. (28035060)
2016
34
Immunohistochemical expression of secreted frizzled receptor protein 1 in the invasive front of tongue squamous cell carcinoma. (26921060)
2016
35
TGFI^1-Smad3-Jagged1-Notch1-Slug signaling pathway takes part in tumorigenesis and progress of tongue squamous cell carcinoma. (26764364)
2016
36
Clinicopathologic Characteristics and Prognosis of Tongue Squamous Cell Carcinoma in Patients with and without a History of Radiation for Nasopharyngeal Carcinoma: a Matched Case-Control Study. (27737535)
2016
37
p53 Expression Helps Identify High Risk Oral Tongue Pre- malignant Lesions and Correlates with Patterns of Invasive Tumour Front and Tumour Depth in Oral Tongue Squamous Cell Carcinoma Cases. (26838208)
2016
38
14-3-3IP silencing retards tongue squamous cell carcinoma progression by inhibiting cell survival and migration. (27080223)
2016
39
Hexokinase 2 enhances the metastatic potential of tongue squamous cell carcinoma via the SOD2-H2O2 pathway. (27926482)
2016
40
FRMD4A: A potential therapeutic target for the treatment of tongue squamous cell carcinoma. (27666346)
2016
41
Development and validation of Raman spectroscopic classification models to discriminate tongue squamous cell carcinoma from non-tumorous tissue. (27531871)
2016
42
The expression and prognostic relevance of indoleamine 2,3-dioxygenase in tongue squamous cell carcinoma. (26982018)
2016
43
Cancer stem cells in moderately differentiated oral tongue squamous cell carcinoma. (27095085)
2016
44
Phosphorylated Epidermal Growth Factor Receptor Expression Is Associated With Clinicopathologic Parameters and Patient Survival in Mobile Tongue Squamous Cell Carcinoma. (27657462)
2016
45
miR-24 promotes the proliferation, migration and invasion in human tongue squamous cell carcinoma by targeting FBXW7. (27350307)
2016
46
TUC338 Overexpression Leads to Enhanced Proliferation and Reduced Apoptosis in Tongue Squamous Cell Carcinoma Cells InA Vitro. (27637778)
2016
47
Decreased expression of Beclina891 is significantly associated with a poor prognosis in oral tongue squamous cell carcinoma. (27356955)
2016
48
Overexpression long non-coding RNA LINC00673 is associated with poor prognosis and promotes invasion and metastasis in tongue squamous cell carcinoma. (28039470)
2016
49
Overexpression of TRIM14 promotes tongue squamous cell carcinoma aggressiveness by activating the NF-I_B signaling pathway. (26799420)
2016
50
Identification of miR-139-5p as a saliva biomarker for tongue squamous cell carcinoma: a pilot study. (26650483)
2016

Variations for Tongue Squamous Cell Carcinoma

About this section

Cosmic variations for Tongue Squamous Cell Carcinoma:

8 (show top 50)    (show all 68)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM6240EGFRupper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.2369C>Tp.T790M13
2COSM11196TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.734G>Tp.G245V13
3COSM33692HRASupper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.185A>Gp.E62G13
4COSM10656TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.742C>Tp.R248W13
5COSM1667029NOTCH1upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.666C>Ap.C222*13
6COSM12504CDKN2Aupper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.247C>Tp.H83Y13
7COSM1737921CDKN2Aupper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.124A>Cp.N42H13
8COSM10834TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.711G>Ap.M237I13
9COSM777PIK3CAupper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.3145G>Ap.G1049S13
10COSM10867TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.797G>Ap.G266E13
11COSM10790TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.455C>Tp.P152L13
12COSM10905TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.451C>Tp.P151S13
13COSM10654TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.637C>Tp.R213*13
14COSM44262TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.808T>Cp.F270L13
15COSM43708TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.422G>Ap.C141Y13
16COSM43621TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.809T>Gp.F270C13
17COSM10648TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.524G>Ap.R175H13
18COSM43841TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.560-1G>Tp.?13
19COSM44351TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.572C>Tp.P191L13
20COSM1667036NOTCH2upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.337C>Tp.R113*13
21COSM12475CDKN2Aupper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.238C>Tp.R80*13
22COSM1667030NOTCH1upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.1237G>Ap.V413M13
23COSM45135TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.673-1G>Tp.?13
24COSM10687TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.527G>Ap.C176Y13
25COSM480HRASupper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.34G>Ap.G12S13
26COSM21436PIK3CAupper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.1028A>Gp.Y343C13
27COSM10992TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.844C>Gp.R282G13
28COSM44411TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.608T>Ap.V203E13
29COSM10939TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.832C>Tp.P278S13
30COSM44523TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.863A>Gp.N288S13
31COSM43814TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.587G>Cp.R196P13
32COSM499HRASupper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.182A>Gp.Q61R13
33COSM10859TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.814G>Tp.V272L13
34COSM10660TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.818G>Ap.R273H13
35COSM10704TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.844C>Tp.R282W13
36COSM10663TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.916C>Tp.R306*13
37COSM13517CDKN2Aupper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.346G>Ap.D116N13
38COSM4654463NOTCH1upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.1239G>Ap.V413V13
39COSM44424TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.590T>Ap.V197E13
40COSM10724TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.839G>Cp.R280T13
41COSM13223CDKN2Aupper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.151-1G>Ap.?13
42COSM12986EGFRupper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.2429G>Ap.G810D13
43COSM308583HRASupper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.53C>Tp.A18V13
44COSM6932TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.733G>Ap.G245S13
45COSM11066TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.578A>Tp.H193L13
46COSM10771TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.749C>Tp.P250L13
47COSM43947TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.614A>Gp.Y205C13
48COSM49170FGFR2upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.758C>Gp.P253R13
49COSM11073TP53upper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.1024C>Tp.R342*13
50COSM521KRASupper aerodigestive tract,tongue,carcinoma,squamous cell carcinomac.35G>Ap.G12D13

Expression for genes affiliated with Tongue Squamous Cell Carcinoma

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Tongue Squamous Cell Carcinoma patients vs. healthy controls: 35 (show all 30)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1MMP1matrix metallopeptidase 1Oral Cavity+6.950.000
2TMPRSS11Btransmembrane protease, serine 11BOral Cavity-5.730.000
3MALmal, T-cell differentiation proteinOral Cavity-5.070.000
4CRNNcornulinOral Cavity-4.970.000
5KRT13keratin 13, type IOral Cavity-4.670.001
6MYH2myosin, heavy chain 2, skeletal muscle, adultOral Cavity-4.120.005
7PTHLHparathyroid hormone-like hormoneOral Cavity+4.090.000
8KRT17keratin 17, type IOral Cavity+3.760.000
9CXCL12chemokine (C-X-C motif) ligand 12Oral Cavity-3.730.000
10LAMC2laminin, gamma 2Oral Cavity+3.680.000
11CLCA4chloride channel accessory 4Oral Cavity-3.650.000
12CXCL1chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)Oral Cavity+3.440.000
13LDB3LIM domain binding 3Oral Cavity-3.410.003
14MMP3matrix metallopeptidase 3Oral Cavity+3.390.000
15CLUclusterinOral Cavity-3.380.000
16WDR66WD repeat domain 66Oral Cavity+3.370.000
17GALNT16polypeptide N-acetylgalactosaminyltransferase 16Oral Cavity-3.360.000
18PRR9proline rich 9Oral Cavity+3.340.004
19CXCL8chemokine (C-X-C motif) ligand 8Oral Cavity+3.330.000
20CRISP3cysteine-rich secretory protein 3Oral Cavity-3.230.010
21CYP4B1cytochrome P450, family 4, subfamily B, polypeptide 1Oral Cavity-3.210.000
22SPINK5serine peptidase inhibitor, Kazal type 5Oral Cavity-3.200.002
23S100A7AS100 calcium binding protein A7AOral Cavity+3.150.001
24IFI6interferon, alpha-inducible protein 6Oral Cavity+3.130.000
25INHBAinhibin, beta AOral Cavity+3.130.001
26KRT4keratin 4, type IIOral Cavity-3.100.000
27ABCA8ATP-binding cassette, sub-family A (ABC1), member 8Oral Cavity-3.100.000
28FAM3Bfamily with sequence similarity 3, member BOral Cavity-3.080.007
29EPPK1epiplakin 1Oral Cavity+3.070.000
30SPRR3small proline-rich protein 3Oral Cavity-3.060.025

Search GEO for disease gene expression data for Tongue Squamous Cell Carcinoma.

Pathways for genes affiliated with Tongue Squamous Cell Carcinoma

About this section

Pathways related to Tongue Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 54)
idSuper pathwaysScoreTop Affiliating Genes
19.9CDH1, CTNNB1
29.8CASP3, CDKN2A, TP53
39.7CDKN2A, MMP2, TP53
49.7CASP3, MMP2, VEGFC
59.7CDH1, CTNNB1, TP53
69.6HIF1A, TP53
79.6HIF1A, TP53
89.6CDH1, CDH2, CTNNB1
99.6HIF1A, VEGFC
109.6CASP3, MMP1, TP53
119.5CTNNB1, NOTCH1, VEGFC
129.5CDH2, CTNNB1, NOTCH1
13
Show member pathways
9.4CASP3, CDH1, CTNNB1, TP53
149.4CASP3, MMP2, MMP9
159.4CDH1, CDH2, MMP9
169.4BMI1, MMP9, TP53
179.4CDH1, CDH2, CTNNB1, TP53
189.4CDKN2A, CTNNB1, MMP2, TP53
199.4CASP3, CTNNB1, MMP9
20
Show member pathways
9.2CTNNB1, HIF1A, VEGFC
21
Show member pathways
9.2MMP1, MMP2, MMP9
229.2MMP1, MMP2, MMP9
239.2BMI1, CDKN2A, MMP14, TP53
249.1CDH1, CDH2, SNAI2
259.1CDKN2A, HIF1A, TP53, VEGFC
269.1CTNNB1, MMP2, MMP9, TP53
279.1BSG, MMP1, MMP9
289.1CDH1, CTNNB1, SNAI2
299.0CASP3, CDH1, CDH2, CTNNB1, NOTCH1
309.0CASP3, CDH1, CTNNB1, MMP1, TP53
318.9CASP3, HIF1A, MMP1, TP53
32
Show member pathways
8.9CASP3, HIF1A, MMP1, TP53
338.9CASP3, MMP14, MMP9, VEGFC
348.9CTNNB1, HIF1A, NOTCH1, TP53
35
Show member pathways
8.8CASP3, CDH1, CTNNB1, HIF1A, TP53
368.7MMP1, MMP14, MMP2, MMP9
37
Show member pathways
8.6CASP3, CDH1, CTNNB1, MMP2, MMP9, TP53
38
Show member pathways
8.6CASP3, CTNNB1, MMP14, MMP2, MMP9
398.5BMI1, CASP3, CDKN2A, MMP9, NOTCH1, TP53
40
Show member pathways
8.5CDH1, CDKN2A, MMP1, MMP2, MMP9, TP53
41
Show member pathways
8.4HIF1A, MMP2, MMP9, NOTCH1, VEGFC
428.4CDH1, CDH2, CTNNB1, NOTCH1, SNAI2
438.4HIF1A, MMP1, MMP2, MMP9, TP53
448.3CASP3, HIF1A, MMP14, MMP2, MMP9
45
Show member pathways
8.3BSG, MMP1, MMP14, MMP2, MMP9
468.3CDH1, CTNNB1, MMP2, MMP9, SNAI2
47
Show member pathways
8.2CDH1, CDKN2A, CTNNB1, MMP2, MMP9, NOTCH1
488.2CASP3, CTNNB1, HIF1A, MMP2, MMP9, TP53
49
Show member pathways
7.9CASP3, CDH1, CDH2, CTNNB1, NOTCH1, SNAI2
507.9BSG, CDH1, CDH2, CTNNB1, MMP14, MMP2

GO Terms for genes affiliated with Tongue Squamous Cell Carcinoma

About this section

Cellular components related to Tongue Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1apical junction complexGO:004329610.4CDH1, CTNNB1
2catenin complexGO:001634210.1CDH1, CDH2, CTNNB1
3fascia adherensGO:000591610.1CDH2, CTNNB1
4adherens junctionGO:000591210.0CDH2, CTNNB1, NOTCH1
5cell-cell adherens junctionGO:00059139.9CDH1, CDH2, CTNNB1
6flotillin complexGO:00166009.9CDH1, CTNNB1

Biological processes related to Tongue Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 31)
idNameGO IDScoreTop Affiliating Genes
1cellular response to indole-3-methanolGO:007168110.7CDH1, CTNNB1
2entry of bacterium into host cellGO:003563510.7CDH1, CTNNB1
3morphogenesis of embryonic epitheliumGO:001633110.6CTNNB1, VEGFC
4replicative senescenceGO:009039910.6CDKN2A, TP53
5cell fate specificationGO:000170810.5CTNNB1, NOTCH1
6positive regulation of protein oligomerizationGO:003246110.5MMP1, TP53
7negative regulation of oligodendrocyte differentiationGO:004871510.5CTNNB1, NOTCH1
8positive regulation of endothelial cell differentiationGO:004560310.5CTNNB1, NOTCH1
9positive regulation of neuron apoptotic processGO:004352510.4CASP3, CTNNB1, TP53
10adherens junction organizationGO:003433210.4CDH1, CDH2, CTNNB1
11cardiac ventricle morphogenesisGO:000320810.2HIF1A, NOTCH1
12positive regulation of transcription from RNA polymerase II promoter in response to hypoxiaGO:006141910.2HIF1A, NOTCH1
13cell migration involved in endocardial cushion formationGO:000327310.0NOTCH1, SNAI2
14epithelial to mesenchymal transition involved in endocardial cushion formationGO:000319810.0NOTCH1, SNAI2
15embryo implantationGO:000756610.0BSG, MMP2, MMP9
16lung developmentGO:003032410.0CTNNB1, MMP14, NOTCH1
17endodermal cell differentiationGO:00359879.9MMP14, MMP2, MMP9
18regulation of osteoblast differentiationGO:00456679.9CTNNB1, SNAI2
19somatic stem cell divisionGO:00481039.8CDKN2A, NOTCH1
20negative regulation of cell proliferationGO:00082859.7CDKN2A, CTNNB1, NOTCH1, TP53, VEGFC
21positive regulation of neuroblast proliferationGO:00020529.6CTNNB1, HIF1A, NOTCH1, VEGFC
22collagen catabolic processGO:00305749.5MMP1, MMP14, MMP2, MMP9
23regulation of gene expressionGO:00104689.4BMI1, CTNNB1, HIF1A, NOTCH1
24positive regulation of apoptotic processGO:00430659.2CASP3, CDKN2A, CTNNB1, MMP9, NOTCH1, TP53
25angiogenesisGO:00015259.2HIF1A, MMP14, MMP2, NOTCH1, VEGFC
26epithelial to mesenchymal transitionGO:00018379.1CTNNB1, HIF1A, NOTCH1, SNAI2
27positive regulation of transcription, DNA-templatedGO:00458939.1CDH1, CDKN2A, CTNNB1, HIF1A, NOTCH1, TP53
28positive regulation of cell migrationGO:00303358.9MMP14, MMP9, NOTCH1, SNAI2
29extracellular matrix disassemblyGO:00226178.8BSG, CDH1, MMP1, MMP14, MMP2, MMP9
30negative regulation of apoptotic processGO:00430668.8CASP3, HIF1A, MMP9, SNAI2, TP53
31response to hypoxiaGO:00016668.8CASP3, HIF1A, MMP14, MMP2, VEGFC

Molecular functions related to Tongue Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1cyclin-dependent protein serine/threonine kinase inhibitor activityGO:000486110.7CASP3, CDKN2A
2gamma-catenin bindingGO:004529510.7CDH1, CDH2
3alpha-catenin bindingGO:004529410.6CDH2, CTNNB1
4protein phosphatase bindingGO:001990310.2CDH2, CTNNB1, TP53
5metalloendopeptidase activityGO:00042229.4MMP1, MMP14, MMP2, MMP9
6metallopeptidase activityGO:00082379.4MMP1, MMP14, MMP2, MMP9
7protein kinase bindingGO:00199019.4CDH2, CDKN2A, CTNNB1, HIF1A, TP53
8enzyme bindingGO:00198999.3CDH2, CTNNB1, HIF1A, NOTCH1, TP53
9peptidase activityGO:00082339.1CASP3, MMP1, MMP14, MMP2, MMP9
10serine-type endopeptidase activityGO:00042528.7MMP1, MMP14, MMP2, MMP9

Sources for Tongue Squamous Cell Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet